ADVERTISEMENT
Addition of Docetaxel to FOLFOX/CAPOX Backbone Fails to Improve OS in Advanced GEJ/Gastric Cancer
Featuring Anant Ramaswamy, MD
Anant Ramaswamy, MD, Tata Memorial Hospital, Mumbai, India, discusses results from the phase 3 DOC-GC study which explored the efficacy of docetaxel added to a FOLFOX/CAPOX backbone for patients with advanced gastroesophageal junction (GEJ) and gastric cancers.
Dr Ramaswamy presented these results at the 2024 ASCO Gastrointestinal Cancers Symposium in San Francisco, California.
Source:
Ramaswamy A, Bhargava PB, Dubashi B, et al. A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/5 fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers (DOC-GC study). Presented at 2024 ASCO Gastrointestinal Cancer Symposium; January 18-20, 2024; San Francisco, California. Abstract LBA248.
© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement